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Genetic linkage analysis of growth factor loci and end-stage renal
disease in African Americans. Hypertension, diabetes mellitus and
chronic glomerular diseases reportedly cause in excess of 80% of the
incident cases of end-stage renal disease (ESRD) in the U.S. The factors
that initiate progressive renal failure in patients with these disorders
remain unknown. Several investigators have reported enhanced synthesis
and activity of cytokines in the kidneys of patients with renal failure. The
ensuing inflammation and fibrosis have been postulated to contribute to
the development of progressive renal failure. There is also abundant
evidence supporting the contribution of genetic factors in ESRD suscep-
tibility based upon the strong familial clustering of ESRD, particularly in
African Americans. Therefore, genetic linkage analysis may be useful to
evaluate the role of candidate genes in several cytokine cascades that
could contribute to the pathogenesis of chronic renal failure. We tested
for genetic linkage between eight cytokine candidate genes and chronic
renal failure in a collection of African American sibling pairs concordant
for ESRD. Epidermal growth factor (EGF), platelet-derived growth factor
(PDGF), transforming growth factor (TGF) /31, TGF-f32 and TGF-133,
and tumor necrosis factor (TNF)-a and TNF-p candidate genes were
selected for analysis due to their putative roles in diabetic renal disease
and chronic glomerulonephritis. The interleukin-1 receptor antagonist
gene (IL1RN) was also genotyped due to its reported association with
diabetic nephropathy. Non-parametric (genetic model independent) af-
fected sib pair linkage analysis was used to evaluate evidence for linkage.
In order to genotype TGF-f33, we identified four closely linked, previously
unidentified, highly polymorphic microsatellite loci near the TGF-/33
gene. Linkage of ESRD and transforming growth factor /32 polymor-
phisms on human chromosome I approached significance for non-diabetic
nephropathy (predominantly chronic glomerular disease, hypertensive
nephrosclerosis and unknown etiology) (P = 0.08), but showed no linkage
to diabetic nephropathy. The other candidate loci did not demonstrate
linkage to ESRD in the total population or in the subgroups with diabetic
or non-diabetic etiologies of ESRD. The ILIRN gene did not show
significant evidence for linkage to ESRD; however, we did confirm an
association between allele 2 of ILIRN and ESRD (as reported in diabetic
nephropathy). Overall, these results suggest that these growth factor loci
do not make major contributions to the pathogenesis of ESRD in African
Americans.
It is unclear why a select minority of patients with the systemic
diseases of hypertension and diabetes mellitus are susceptible to
progressive renal failure and ultimately ESRD. African Amen-
Received for publication June 20, 1996
and in revised form September 11, 1996
Accepted for publication September 12, 1996
© 1997 by the International Society of Nephrology
cans are disproportionately affected with all the common etiolo-
gies of ESRD relative to Caucasians, including ESRD attributed
to hypertension, non-insulin-dependent diabetes mellitus (NIDDM)
and chronic glomerulonephritis (CGN) [1]. Genetic factors may
account for a portion of the racially disparate incidence rates of
ESRD, based upon the familial aggregation of ESRD in African
Americans from different geographic regions of the U.S. [2—41.
Racial differences in socio-economic status and environmental
exposure, although present, do not appear to fully account for the
variable risk of ESRD [5, 6]. A biologic cause for chronic renal
failure susceptibility is further supported by close relatives having
different etiologies of ESRD in African American multiplex renal
failure families [2—4]. Renal failure genes have already been
identified in the fawn-hooded rat, an inbred animal model of
glomeruloselerosis and hypertension [7]. Taken together, these
findings suggest that "renal failure genes" may exist in high risk
families.
The current report addresses whether there is linkage between
chronic renal failure and candidate genes related to cytokine
cascades in a high risk African American population. We studied
eight cytokine-related candidate loci implicated in the pathogen-
esis of progressive renal disease [8, 9], IgA nephropathy [10, 111,
focal and segmental glomerulosclerosis [10], membranous gb-
merulonephritis [11], lupus nephritis [12, 13], HIV nephropathy
[14] and diabetic nephropathy [15—17]. These loci included:
epidermal growth factor (EGF), platelet-derived growth factor /3
(PDGF/3); transforming growth factor-f31 (TGF-/31); TGF-/32;
TGF-p3, tumor necrosis factor (TNF)-a, TNF-/3 and the interlcu--
kin-I receptor antagonist (ILl RN). These candidate genes were
tested for linkage in our collection of African American sibling
pairs concordant for the common etiologies of ESRD.
Methods
Study population
The study population consisted of 115 African American sibling
pairs (200 patients) concordant for ESRD from 99 families.
Diabetics with overt proteinuria ( 100 mg/dl on dipstick or 500
mg/24 hr) were analyzed as having ESRD, due to the nearly
universal progression to renal replacement therapy [18]. Sibling
pairs were identified by the screening of all prevalent African
American hemodialysis patients from ten large dialysis facilities in
North Carolina and Virginia, and using the "Family History of
819
820 Freedman et al: Linkage analysis of cytokines and ESRD
ESRD" database completed on all incident patients in dialysis
facilities in the ESRD Network 6 (more than 250 dialysis facilities
in Georgia, North Carolina and South Carolina). Sibling pairs
who self-reported their race as African American and who were
concordant for ESRD were asked for permission to have their
existing medical records reviewed and to provide blood samples
for DNA isolation and/or creation and storage of immortalized
cell lines. Exclusion criteria were siblings in whom either member
had renal failure attributable to the known genetic entities of
adult polycystic kidney disease (P1(D) or Alport's syndrome(hereditary nephritis), ESRD attributable to urologic disease
(urinary reflux or surgical nephrectomy), age less than 18 years,
inability to provide informed consent or self-reported race other
than African American.
The causes of renal failure were assigned by a single investiga-
tor after review of available medical records from the treating
nephrologist. The following information was requested in all
cases: renal biopsy results; pre-dialysis urinalysis and timed urine
collection for protein excretion; presence, age at onset and mode
of treatment for diabetes, hypertension; the presence of systemic
lupus erythematosus (SLE), PKD, Alport's syndrome, human
immunodeficiency virus (HIV) infection or renal artery stenosis;
and daily ingestion of analgesics or "moonshine" for more than
one year. Clinical data were available in the sibling pairs as
follows: 97% of cases provided historical information regarding
treatment of hypertension and diabetes, 56% had at least one
pre-dialysis urinalysis, 24% had a timed urine collection, and 8%
of patients had a kidney biopsy.
The renal biopsy diagnosis was applied in all patients who
received a biopsy. Diabetic nephropathy was diagnosed in the
presence of diabetes mellitus duration greater than 10 years
(typically with proteinuria  100 mg/dl or 500 mg/24 hr when this
data were available). NIDDM was diagnosed in patients never
having diabetic ketoacidosis, diagnosed with diabetes after the age
of 30 years or treated with oral agents or dietary therapy for one
year after initial diagnosis. Hypertensive nephropathy was diag-
nosed in the presence of hypertension greater than 10 years
duration when proteinuria < 30 mg/dI or 500 mg/24 hr was
present. Chronic glomerulonephritis was diagnosed in patients
with systemic diseases other than diabetes mellitus known to
produce CGN (that is, SLE or HIV), proteinuria  100 mg/dl or
500 mg/24 hr and/or moderate hematuria with or without urinary
red blood cell casts. Cases were classified as unknown cause if
insufficient clinical data were available, particularly lack of a
pre-dialysis urinalysis or urine collection in non-diabetics.
Cienolyping
Genotypes at polymorphic sites for the following seven growth
factor genes were determined: epidermal growth factor (EGF),
platelet-derived growth factor beta (PDGF), transforming
growth factor-beta 1 (TGF-pl), TGF-2, TGF-3, tumor necrosis
factor-alpha (TNF-cr) and TNF-p (lymphotoxin). In addition, the
gene for interleukin-1 receptor antagonist (ILIRN) was evalu-
ated. Genotyping was done by the polymerase chain reaction
(PCR) using highly polymorphic microsatellite markers. A total of
13 polymorphic markers were used to genotype the eight candi-
date genes. Primers with prefix D were purchased from Research
Genetics (Huntsville, AL, USA). All others were synthesized by
the DNA Synthesis Core Facility of the Bowman Gray School of
Medicine.
D4S193, which is 2.0 CM away from EGF on chromosome 4 [191
was used as the marker for EGF. Genotyping of PDGFI3 (the SIS
locus) was done using the marker PDGFI3. PCR1 [20]. TGF-pl is
flanked by D19S200 and D19S197 in map C19M52 in the
Genomic Data Base (GDB; site http://gdbwww.gdb.org; L. Ash-
worth and H. Mohrenweiser, personal communication). The
distance between these two markers is 0.6 CM, according to the sex
average recombination minimization map version 4.0 in the
Cooperative Human Linkage Center (CHLC; site http://www.chlc.-
org) [21]. Thus, TGF-f31 is within 0.6 CM of either marker and
D19S200 was chosen as the marker for TGF-/31. TGF-f32 was
genotyped using marker D1S227, 1.3 CM distant [22]. TNF-a was
genotyped with markers TNFd and TNFe [23], while TNF-p was
genotyped with markers TNFa and TNFb [24]. The IL1RN gene
was genotyped with a tandem repeat polymorphism in intron 2
[25]. We identified new markers for TGF-/33, described in detail
in the Results, since no suitable markers had been developed.
Polymerase chain reaction was carried out in microtiter plates
in either Hybaid/Omni Gene or Perkin-Elmer/9600 thermal cy-
clers. The 7.5 l reaction solution contained 10 m'vi Tris-HCI, pH
8.3, 50 m'vi KC1, 1.5 mivi MgC12, 200 /kM dNTPs, 0.8 mM spermi-
dine, 30 ng each primer, 0.35 units Taq, and 75 ng genomic DNA
and was covered with 42 jsl mineral oil. The reaction mixture also
included 4.5 ng one primer end-labeled with [y32P]dATP. The
typical PCR profile comprised the initial soak at 94°C for three
minutes, then 10 cycles of 94°C for one minute, annealing
temperature for one minute, and 72°C for one minute, followed by
15 cycles of 92°C for one minute, annealing temperature for one
minute and 72°C for one minute, and was completed by the final
incubation at 72°C for three minutes.
Polymerase chain reaction for the TNF markers was carried out
in two steps: an initial cold PCR reaction followed by PCR
incorporating radioactive label. Products of the cold PCR were
used as substrate for subsequent PCR in which one primer was
end-labeled in the usual manner. The total number of cycles in the
hot PCR was reduced to 10. For TNFa and TNFb, the cold PCR
was carried out with primers IRI and 1R2. Then, the TNFa
polymorphism was amplified in the radioactive PCR with primers
1R2 and 1R4 (1R4 end-labeled), while TNFb was amplified with
IR1 and 1R5 (1R5 end-labeled). For TNFd and TNFe the cold
PCR was carried out with primers IR11 and 1R14. Then the TNFd
polymorphism was amplified in the radioactive PCR reaction with
primers IR11 and 1R12 (1R12 end-labeled), while TNFe was
amplified with primers 1R13 and 1R14 (1R13 end-labeled).
Products of microsatcllite marker amplification were manually
analyzed electrophoretically on standard 6% acrylamide sequenc-
ing gels [261. The identity of these markers was confirmed by their
product lengths in base pairs determined with the co-run DNA
sequencing ladder.
Data analysis
Phenotype and genotype data available in the 115 sib pairs from
the 99 African American families were analyzed using the sib-pair
(SIBPAL) program of S,A.G.E. [27]. Sib-pair tests were per-
formed to detect linkage between genetic markers and the disease
(ESRD). The data were analyzed in the total population (115 sib
pairs) and in the subgroups concordant for non-insulin-dependent
diabetes mellitus associated ESRD (56 sib pairs) and non-diabetic
etiologies of ESRD (59 sib pairs). Linkage is detected when the
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Table 1. Growth factor genes evaluated in African American families with ESRD
Gene
Chromosomal
location
Marker
name Heterozygosity Relation to gene Reference
—
EGF 4q25 D4S193 0.75 2.0 cM [191 NIH/CEPH, 1992
TURN 2q14.2 IL1RN 0.41 intron 2 [25] Tarlow et al, 1993
PDGFP 22q12.3-q13.l PDGFB.PCR1 0.57 4.7 kb upstream [20] Patterson et al, 1990
TGF-f3l 19q13.2 D19S200 0.88 <0.6 CM GDB, CHLC (WWW)
TGF-p2 1q41 D1S227 0.68 1.3 CM [22] Kimberling et al, 1995
TGF-f33 14q24 D14S61
D14S71
D14S270
D14S273
0.81
0.75
0.69
0.71
within same YAC
4.0 CM
within same YACU
1.0 CM
Present study
[32] Gyapay et al, 1994
Present study
[32] Gyapay et al, 1994
TNF-a 6p2l.3 TNFd
TNFe
—
—
8—10 kb downstream
8—10 kb downstream
[231 Udalova et al, 1993
[23] Udalova et al, 1993
TNF-p op2l.3 TNFa
TNFb
0.87
0.73
3.5 kb upstream
3.5 kb upstream
[24] Nedospasov et al, 1991
[24] Nedospasov et al, 1991
Yeast artificial chromosome
mean estimated proportion of alleles that sib-pairs share identi-
cally by descent (IBD) at a marker locus is significantly greater
than 0.5 (the expected proportion under the null hypothesis of "no
linkage"). An advantage of SIBPAL is that it uses all of the
available data from nuclear families to calculate the proportion of
alleles shared IBD among all pairs of siblings. Based upon the
methods of Risch [28, 29], the power to detect linkage in this data
set is a function of the risk to siblings (As). We have previously
shown that the estimate of A. approaches 10 in similar patient
populations [3, 30]. Further, using the relationship from Risch [28,
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T = n0 log (nJN,) + (N — n0) log [(N — n0)/(n0 — Ncs0)]
where N is the total sample size, a, is the proportion of affected
sibling pairs expected to share 0 alleles IBD under Mendelian
inheritance, and n0 is the number of individuals observed to share
0 alleles IBD, the power for this data set can be approximated. For
100 affected sib pairs, the expectation under Mendelian inheri-
tance is 25 sib pairs sharing zero alleles IBD. The power to detect
linkage is then obtained by calculating the probability that fewer
sib pairs than n0 are found to share 0 alleles IBD, given the
proportion of sib pairs that are expected to share 0 alleles IBD
and the sample size. For a sample of 100 affected sib pairs, n0
needs to be less than 10 pairs to achieve a T > 3, equivalent toP <
0.001. For a A of 10, we have nearly 100% power to detect a
linked locus with recombination (0) = 0 (such as a candidate
locus), 90% power to detect a linked locus with U = 0.05, and 50%
power to detect a locus with 0 0.10. For subgroup analysis, with
a sample of 50 affected sib pairs, the power is significantly
decreased (75% power to detect a candidate locus).
In addition, exclusion analysis was performed with the MAP-
MAKER/SIBS program [31]. The exclusion program calculates
maximum lod scores (MLS) based upon A. (disease risk for a
sibling). An MLS of —2.0 or less is considered strong evidence for
rejection of linkage.
We calculated reference allele frequencies by sampling the first
person from each African American ESRD family on our pedi-
gree list. This was performed since published allele frequencies
for the markers tested were from Caucasians and no data were
available in African Americans.
Results
Previously identified markers for each candidate gene were
available except for TGF-f33. In order to identify TGF-133 poly-
morphisms, a pair of PCR primers specific for TGF-/33 were
synthesized based upon available genomic sequences (TGF-f33:
5 '-TCGAACGAGAGGACTCGCAA; TGF-3-2: 5 '-CGCTCAT-
TCCCTTGGACTTGA). This pair of primers amplifies a 294 bp
DNA fragment in the promoter region of TGF-f33. These primers
were used to screen yeast artificial chromosome (YAC) library
poois from the CEPH (Centre D'Etude Polymorphism Humain)
YAC libraries purchased from Research Genetics (Huntsville,
AL, USA) by PCR. One YAC containing the TGF-133 gene,
yh749A2, was identified. After the YAC clone was identified,
DNA from the YAC was extracted and used in PCR reactions
with the TGF-f33 primers to ensure that the selected clone
contained the TGF-133 gene. DNA from this YAC clone sup-
ported PCR amplification using TGF-J33 gene primers, but the
yeast genomic DNA did not support PCR, confirming that this
clone contained the TGF-/33 gene and the chromosome 14
location of TGF-p3. A search of the Baylor College of Medicine!
Human Genome Center YAC database (site: http:!!gc.bcm.
tmc.edu.8088) revealed that several mierosatellite polymorphisms,
D14S61 and D14S270, were in the same YAC clone containing
the TGFI33 gene and two others, D14S71 and D14S273, were
closely linked. The assignment of D14S61 and D14S270 to the
TGF-J33 coiitaining-YAC yh749A2 was also verified by PCR
amplifying with primers for these two markers on DNA from this
YAC. Genotyping of TGF-3 was done with D14S61, D14S270,
D14S273 and D14S71 (the latter two are chromosome 14 markers
1.0 CM and 4,0 CM from D14S61, respectively) [32]. Table 1
summarizes the 13 markers that were used to genotype the eight
growth factor or related candidate genes.
The estimated proportion of marker alleles shared IBD are
listed in Table 2. In the overall data set encompassing the 115
potentially informative ESRD sib pairs, the proportion of candi-
date genes shared JBD varied from a low of 0.444 for TGF-/33
(D14S71 marker) to a high of 0,530 for TGF-/31 (D19S200
marker). None of the eight candidate genes tested had IBD
significantly different from 0.5. When the data were stratified by
etiology, no significant evidence for linkage was found in the
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Table 2. Results of the affected sib-pair analysis using SIBPAL of SAGE
Total population NIDDMESRDa NON-DM ESRDh
Gene Marker NC IBD' P N' IBD' P NC IBD p
EGF D4S193 76 0.508 0.401 30 0.522 0.309 46 0.498 1.000
TL1RN ILIRN 115 0.502 0.434 56 0.517 0.198 59 0.488 1.000
PDGFI3 PDGFp.PCR1 83 0.518 0.276 37 0.494 1.000 46 0.537 0.204
TGF-f31 D19S200 82 0.530 0.167 36 0.503 0.474 46 0.551 0.133
TGF-f32 D1S227 82 0.525 0.153 38 0.491 1.000 44 0.548 0.084
TGF-133 D14S61 77 0.528 0.222 33 0.522 0.346 44 0.536 0.243
D14S71 84 0.444 1.000 38 0.391 1.000 46 0.488 1.000
D14S270 83 0.454 1.000 38 0.440 1.000 45 0.466 1.000
D14S273 83 0.484 1.000 37 0.481 1.000 46 0.486 1.000
TNF-a TNFd 84 0.502 0.473 38 0.489 1.000 46 0.517 0.330
TNFe 84 0.496 1.000 38 0.497 1.000 46 0.495 1.000
TNF-13 TNFa 85 0.496 1.000 38 0.484 1.000 47 0.507 0.444
TNFb 85 0.489 1.000 38 0.473 1.000 47 0.502 0.481
a Non-insulin-dependent diabetes mellitus-associated ESRD
b Non-diabetic etiologies of ESRD (hypertension, chronic glomerulonephritis and unknown)
C Number of sibling pairs
d Estimated proportion of marker alleles shared identical by descent
Table 3. Exclusion analysis using MAPMAKERISIBS
Maximum lod score (MLS) at A
Gene Marker Family type 1.2 1.5 2 3 5 10
EGF D4S193 All families —0.76 —1.89 —3.50 —5.86 —8.82 —11.87
Diabetic 0.10 0.10 0.00 —0.27 —0.67 —1.27
Non-diabetic —0.19 —0.55 —1.11 —1.96 —3.02 —4.41
IL1RN IL1RN All families —0.84 —1.85 —3.08 —4.61 —6.15 —7.70
Diabetic 0.14 0.24 0.28 0.26 0.19 0.12
Non-diabetic —0.32 —0.71 —1.17 —1.71 —2.24 —2.68
PDGFI3 PDGF/3.pcrl All families —0.78 —1.95 —3.63 —6.14 —9.37 —13.3
Diabetic —0.07 —0.25 —0.58 —1.17 —1.84 —2.85
Non-diabetic 0.04 —0.08 —0.41 —1.08 —2.05 —3.48
TGF-f31 D19S200 All families —0.54 —1.46 —2.89 —5.13 —8.07 —12.04
Diabetic —0.11 —0.31 —0.65 —1.17 —1.86 —2.75
Non-diabetic 0.37 0.57 0.58 0.33 —0.21 —1.09
TGF-/32 D1S227 All families —0.64 —1.59 —2.95 —4.95 —7.46 —10.75
Diabetic 0.00 —0.09 —0.26 —0.54 —0.89 —1.32
Non-diabetic 0.03 —0.06 —0.3 —0.76 —1.41 —2.34
TGF-133 D14S61, All families —1.48 —3.51 —6.27 —10.26 —15.22 —21.39
D14S270,
D14S273, D14S71
Diabetic —0.56 —1.37 —2.54 —4.26 —6.42 —9.17
Non-diabetic —0.22 —0.66 —1.44 —2.66 —4.21 —6.11
TNF-a,f3 TNFa,b,d,e All families —0.99 —2.57 —4.94 —8.59 —13.38 —19.92
Diabetic —0.04 —0.33 —0.94 —2.04 —3.64 —5.93
Non-diabetic
-
—0.08 —0.40 —1.04 —2.15 —3.72 —5.93
NIDDM-associated ESRD sib pairs (Table 2). However, the IBD
for TGF-132 approached significance at 54.8% sharing I BD in the
non-diabetic ESRD sib pairs (P = 0.084).
In addition to affected sib pair analysis, we carried out an
exclusion analysis of the data using the program MAPMAKER!
SIBS 31, 321. This approach is designed to provide support for
evidence against linkage between a trait (ESRD) and a region of
the chromosome based upon specific hypothesized relative risks.
Practically speaking, these calculations give the investigator a
sense of whether a specific genetic locus (that is, a growth factor
candidate gene) can be excluded from contributing a specific
relative risk (A) toward expression of a trait. Results of these
analyses are shown in Table 3. With the combined data each of the
candidate genes can be excluded (MLS of < —2.0) from contrib-
uting a relative risk to a sibling of 2 or greater. In the case of the
TNF and TGF-p3 loci at which multiple closely linked markers
were genotyped, these loci can be excluded from contributing a
relative risk of 1.5 or greater. When the families are stratified into
ESRD due to diabetes and non-diabetic ESRD, exclusions are
less significant. With the stratified data, two markers TGF-131 and
IL1RN show positive MLS for values of A. TGF-j31 had positive
MLS of 0.57 to 0.58 at A of 1.5 to 2.0, and IL1RN shows mildly
positive MLS for values of A. The ILIRN marker is poorly
polymorphic having one major allele. The inability to exclude is
probably a reflection of a lower polymorphism or small sample
size.
Table 4 shows the allele frequencies of IL1RN in the non-
ESRD, healthy African American control population (North
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Table 4. Interleukin-1 receptor antagonist (IL1RN) allele frequencies
ILl RN Alleles, N (%)
1 2 3 4
Healthy controls 154 (90.6%) 14 (8.2%) 0 (0%) 2 (1.2%)
All ESRD families 344(86%) 49(12.2%) 3 (0.8%) 4(1%)
Diabetic ESRD 141 (87%) 21(13%) 0(0%) 0 (0%0
Non-diabetic ESRD 203(85.3%) 28 (11.8%) 3 (1.2%) 4 (1.7%)
Carolina Baptist Hospital employees) and the ESRD populations.
Allele 2 accounted for 13% and 11.8% in the diabetic and
non-diabetic ESRD sib pairs, respectively. Overall, allele 2 ac-
counted for 12.2% of the ESRD population. These percentages
are all significantly higher than the 8.2% observed in the control
population. Evaluation of the allele effect on ESRD using the
relative predispositional effect technique [33] indicated that allele
2 had a significant association with ESRD in the total population
(C2 = 11.6; P = 0.00068), confirming a prior report in diabetic
nephropathy.
Discussion
This is the first report of linkage analyses using growth factors
as candidate genes for linkage to ESRD in this high risk African
American population. The family collection included sibling pairs
with renal failure attributed to NIDDM, CGN and hypertension.
Currently, these three diagnoses account for more than 80% of
incident ESRD cases. These results demonstrate the absence of
significant evidence for genetic linkage between the EGF,
PDGF/3, TGF-pl-3, TNF-cs and TNF-f3 loci in African Americans
with common etiologies of ES RD. This lack of departure from the
proportion of 0.5 alleles shared at the marker loci in the affected
sib pairs excludes the hypothesis that common polymorphisms in
these growth factor loci could have important effects on the
development of chronic renal failure. The analysis of more
homogeneous subsets of ESRD sibling pairs, possibly enriched for
a genetic component, were also negative. Exclusion analysis,
calculating maximum lod scores, complemented the affected sib
pair analysis and confirmed that there is little or no evidence for
linkage of these candidate genes to ESRD with the possible
exceptions of TGF-/32 and TGF-fll (MLS of 0.57-0.58 in MAP-
MAKER/SIBS analysis) in non-diabetic sibling pairs. Additional
families and additional genetic markers will have to be analyzed in
order to clarify whether these loci contribute significantly to
ESRD in non-diabetic families. Significantly, the results for
TGF-f31 and TGF-p2 using two independent analytical ap-
proaches were not consistent, suggesting the mildly positive
results are due to Type 1 errors. When multiple markers were
genotyped within the same region, such as the TNF and TGF-3
loci, exclusions were more powerful, suggesting multiple markers
are a powerful method for evaluating candidate genes and re-
gions. In addition, as we demonstrated in the TGF-3 locus,
closely linked, highly polymorphic markers can frequently he
identified for markers which have no previously identified, asso-
ciated polymorphism.
The ILIRN or interleukin-1 receptor antagonist gene was
genotyped in addition to the growth factor loci. This analysis was
performed due to its reported association with diabetic nephrop-
athy [17]. While we found no evidence for linkage between IL1RN
and ESRD, we could not exclude linkage in diabetic ESRD
families. We also observed an association between allele 2 of this
polymorphism and diabetic ESRD as reported by Blakemore and
colleagues [171. It will be of considerable interest to re-evaluate
this locus as our family collection increases and when additional
closely linked polymorphic markers, identified in a manner similar
to TGF-133, are discovered.
Alterations in the structure or function of growth factors are
likely to be associated with the progressive fibrosis and scarring
that develops in patients with ESRD [34, 35]. The growth factors
we used as candidate genes are all associated with development of
progressive renal disease. Growth factors are attractive candidate
genes in renal failure since multiply affected African American
ESRD families often have members with disparate etiologies of
ESRD. This suggests that a hereditary factor leading to renal
destruction may be present in these families and produce ESRD
in the presence of diabetes, hypertension or HIV infection in
different members of these kindreds. Glomerular abnormalities in
the nephropathies caused by diabetes, glomerulonephritis and
hypertension are clearly different. However, glomeruli account for
only 5% of renal mass, while the interstitium accounts for the
majority of renal tissue. Interstitial fibrosis is an excellent predic-
tor of progressive renal failure from a variety of different renal
diseases [36]. Therefore, abnormal cytokine gene mutations could
make an individual more susceptible to renal interstitial fibrosis in
association with several systemic illnesses. This single abnormality
could produce renal failure from multiple etiologies. Although
this study demonstrates the lack of linkage between these genes
and ESRD, it remains possible that polymorphisms in other
growth factor loci or in the receptors for these growth factors
could still produce renal failure. Unusual polymorphisms of these
genes could have made important contributions to ESRD, yet
only accounted for a small percentage of patients in the study
population. Additionally, our findings should be restricted to this
study population and additional linkage analyses in Native Amer-
ican, Asian American and Caucasian populations would be of
interest.
A potential limitation of this, and other, studies in ESRI)
populations lies in our ability to accurately determine the cause of
ESRD. We placed patients with glomerular disease, hypertension
and unknown non-diabetic etiologies of ESRD in a single group,
since it is often difficult to clearly differentiate these disorders
when renal biopsy material is lacking. It is clear that African
Americans with nephropathy typically present to physicians in the
late stages of their illness [371. It may be impossible to determine
the exact factor(s) initiating their renal failure. This difficulty
plagues epidemiologic and physiologic analyses as well [38, 39].
The molecular genetic approach is particularly well suited to
detecting subsets of patients with renal failure who share a
common genetic predisposition, therefore the phenotype
"ESRD" is useful. Essential hypertension, like ESRD, is a heter-
ogeneous disorder with many different etiologies. In a report of
angiotensinogen gene (AGT) linkage to hypertension, angio..
tensinogen was estimated to play a role in only 5% of hypertcn-•
sives, yet it was easily detected using 200 affected sibling pairs [40]
We believe that the qualitative phenotype "ESRD," regardless
of its cause, is of importance. This is supported by three indepen-
dent reports that reveal clustering of disparate etiologies of ESRD
in single African American families [2—4]. Affected members from
these families may have inherited susceptibility to renal failure,
that is, renal failure genes, that may be triggerred by factors such
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as hyperglycemia, hypertension or HIV infection. Similarly, sus—
ceptibility to renal disease from diabetes appears to be distinct
from the presence of hyperglycemia per se [30, 41, 42]. It appears
likely that renal failure genes are inherited in certain diabetic
families independently from the inherited and environmental
factors producing hyperglycemia, insulin resistance or destruction
of pancreatic beta islet cells. Renal failure genes have already
been identified in inbred animal strains with hypertensive neph-
rosclerosis [71.
In summary, while not all possible growth factor and cytokine
candidate genes were tested, polymorphisms in the EGF, PDGFI3,
TGF-/31, TGF-132, TGF-j33, TNF-ts, TNF-/3 and ILl RN loci do
not appear to play major roles in the initiation of renal failure in
African Americans with the three most frequently reported
etiologies of ESRD. In the future, linkagc analyses are likely to
determine the inherited factors producing chronic renal failure.
We are evaluating additional candidate genes for linkage to
ESRD, including adrenergic receptor genes and human homo-
logues of rodent renal failure genes. The identification of human
renal failure genes will allow for physiologic investigations to be
performed in genetically homogeneous populations. Ultimately,
the protein products of these genes may serve as targets to prevent
the development and progression of chronic renal failure.
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